Mizuho raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $87 and keeps an Outperform rating on the shares post the Q2 report. The company posted a strong performances across its portfolio, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Early notable gainers among liquid option names on July 25th
- Edwards Lifesciences price target raised to $95 from $90 at Stifel
- Edwards Lifesciences price target raised to $80 from $77 at Evercore ISI
- Edwards Lifesciences price target raised to $79 from $78 at Baird
- Edwards Lifesciences price target raised to $89 from $85 at RBC Capital